



HAL
open science

A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study

Roland Richard Tilz, Vanessa Schmidt, Helmut Pürerfellner, Philippe Maury, K Chun, Martin Martinek, Christian Sohns, Boris Schmidt, Franck Mandel, Estelle Gandjbakhch, et al.

► **To cite this version:**

Roland Richard Tilz, Vanessa Schmidt, Helmut Pürerfellner, Philippe Maury, K Chun, et al.. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. *European Heart Journal*, 2023, 44 (27), pp.2458-2469. 10.1093/eurheartj/ehad250 . hal-04586477

HAL Id: hal-04586477

<https://ube.hal.science/hal-04586477v1>

Submitted on 24 May 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study

Roland Richard Tilz ^{1,2,*†}, Vanessa Schmidt^{1†}, Helmut Pürerfellner³, Philippe Maury ⁷, KR Julian Chun⁶, Martin Martinek ³, Christian Sohns ⁴, Boris Schmidt ⁶, Franck Mandel⁷, Estelle Gandjbakhch ⁸, Mikael Laredo ⁹, Melanie Anuscha Gunawardene¹⁰, Stephan Willems ¹⁰, Thomas Beiert¹¹, Martin Borlich¹², Leon Iden¹², Anna Fütting^{13,14}, Raphael Spittler¹⁵, Thomas Gaspar¹⁶, Sergio Richter¹⁶, Anja Schade¹⁷, Malte Kuniss ¹⁸, Thomas Neumann¹⁸, Alexander Francke¹⁹, Carsten Wunderlich¹⁹, Dong-In Shin^{20,21}, Dirk Grosse Meininghaus ²², Mike Foresti²³, Marc Bonsels²³, David Reek²⁴, Uwe Wiegand²⁵, Alexander Bauer²⁶, Andreas Metzner ²⁷, Lars Eckardt ²⁸, Sorin Ștefan Popescu¹, Olaf Krahnfeld²⁹, Christian Sticherling ³⁰, Michael Kühne³⁰, Dinh Quang Nguyen³¹, Laurent Roten ³², Ardan M. Saguner³³, Dominik Linz³⁴, Pepijn van der Voort³⁵, Bart A. Mulder³⁶, Johan Vijgen³⁷, Alexandre Almorad³⁸, Charles Guenancia³⁹, Laurent Fauchier ⁴⁰, Serge Boveda ^{41,38}, Y. De Greef^{42,38}, Antoine Da Costa⁴³, Pierre Jais⁴⁴, Nicolas Derval⁴⁴, Antoine Milhem⁴⁵, Laurence Jesel⁴⁶, Rodrigue Garcia ⁴⁷, Hervé Poty⁴⁸, Ziad Khoueiry⁴⁹, Julien Seitz⁵⁰, Julien Laborderie⁵¹, Alexis Mechulan⁵², Francois Brigadeau⁵³, Alexandre Zhao⁵⁴, Yannick Saludas⁵⁵, Olivier Piot ⁵⁶, Nikhil Ahluwalia^{57,58}, Claire Martin⁵⁹, Jian Chen ⁶⁰, Bor Antolic⁶¹, Georgios Leventopoulos⁶², Emin Evren Özcan⁶³, Hikmet Yorgun⁶⁴, Serkan Cay ⁶⁵, Kivanc Yalin ⁶⁶, Maichel Sobhy Botros⁶⁷, Ahmed Taher Mahmoud⁶⁷, Ewa Jędrzejczyk-Patej⁶⁸, Osamu Inaba⁶⁹, Ken Okumura⁷⁰, Koichiro Ejima⁷¹, Houman Khakpour⁷², Noel Boyle⁷², John N. Catanzaro⁷³, Vivek Reddy⁷⁴, Sanghamitra Mohanty⁷⁵, Andrea Natale ^{75,76,77}, Hermann Blessberger⁷⁸, Bing Yang⁷⁹, Irene Stevens¹, Philipp Sommer⁴, Christian Veltmann⁵, Daniel Steven ⁸⁰, Julia Vogler ¹, Karl-Heinz Kuck ¹, José Luis Merino⁸¹, Ahmad Keelani^{1†}, and Christian-H. Heeger ^{1,2,*†}

¹Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, D-23538 Lübeck, Germany; ²German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany; ³Ordensklinikum Linz Elisabethinen, Linz, Austria; ⁴Kliniken für Elektrophysiologie/Rhythmologie,

* Corresponding authors. Tel: +49 451 500 44511, Fax: +49 451 500 44585, Email: tilz6@hotmail.com (R.R.T.); Tel: +49 451 500 75293, Fax: +49 451 500 44585, Email: christian.heeger@gmx.net (C.H.H.)

† The first and last two authors contributed equally to the study.

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany; ⁵Heart Center Bremen, Electrophysiology Bremen, Bremen, Germany; ⁶MVZ CCB am Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany; ⁷Department of Cardiology, University Hospital Rangueil, Toulouse, France; ⁸Sorbonne Université, APHP, Pitié Salpêtrière University Hospital, Cardiology Institute, Paris, France; ⁹APHP, Pitié Salpêtrière University Hospital, Cardiology Institute, Paris, France; ¹⁰Klinik für Kardiologie und Internistische Intensivmedizin, Asklepios Klinik St. Georg, Hamburg, Germany; ¹¹Heart Center Bonn, Department of Internal Medicine II, University Hospital Bonn, Bonn, Germany; ¹²Heart Center, Segeberger Kliniken (Academic Teaching Hospital of the Universities of Kiel, Lübeck and Hamburg), Bad Segeberg, Schleswig-Holstein, Germany; ¹³Department of Electrophysiology, Alfred Krupp Hospital, Essen Germany; ¹⁴Department Of Medicine, Witten/Herdecke University, Witten, Germany; ¹⁵Department of Cardiology II/Electrophysiology, Center for Cardiology, University Hospital Mainz, Mainz, Germany; ¹⁶Department of Internal and Cardiovascular Medicine, Herzzentrum Dresden, University Clinic, Technische Universität Dresden, Dresden, Germany; ¹⁷Department of Interventional Electrophysiology, Helios Hospital Erfurt, Erfurt, Germany; ¹⁸Department of Cardiology Kerckhoff Heart Center, Bad Nauheim, Germany; ¹⁹Helios Klinikum Pirna, Klinik für Innere Medizin II, Pirna, Germany; ²⁰Department of Cardiology, Heart Centre Niederrhein, Helios Clinic Krefeld, Krefeld, Germany; ²¹Faculty of Health, School of Medicine, University Witten/Herdecke, Witten, Germany; ²²Department of Cardiology, Carl-Thiem-Klinikum gGmbH Cottbus, Cottbus, Germany; ²³Kliniken Maria Hilf GmbH, Mönchengladbach, Germany; ²⁴Department of Cardiology, University Hospital Augsburg, Augsburg, Germany; ²⁵Sana-Klinikum Remscheid GmbH, Akademisches Lehrkrankenhaus der Universität zu Köln, Remscheid, Germany; ²⁶Diak-Klinikum Schwäbisch Hall und Klinikum Crailsheim, Schwäbisch Hall, Germany; ²⁷Universitäres Herz- und Gefäßzentrum, Klinik für Kardiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; ²⁸Department of Cardiology II (Electrophysiology), University Hospital Münster, Germany; ²⁹Sana Kliniken Lübeck, Lübeck, Germany; ³⁰Department of Cardiology, University Hospital Basel, Münster, Switzerland; ³¹St. Vinzenz-Hospital Köln, Köln, Germany; ³²Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Basel, Switzerland; ³³Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland; ³⁴Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; ³⁵Catharina Hospital, Eindhoven, The Netherlands; ³⁶Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; ³⁷Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium; ³⁸Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel—Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium; ³⁹Cardiology Department, Dijon University Hospital, Dijon, France; ⁴⁰Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France; ⁴¹Cardiology—Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France; ⁴²Department of Cardiology, ZNA Heart Centre, Antwerp, Belgium; ⁴³Division of Cardiology, Jean Monnet University, Saint-Etienne, Crêteil, France; ⁴⁴CHU Bordeaux, Univ. Bordeaux, IHU LIRYC ANR-10-IAHU-04, France; ⁴⁵La Rochelle Hospital, France; ⁴⁶University Hospital Strasbourg, France; ⁴⁷University Hospital Poitiers, France; ⁴⁸Clinique Tonkin, Lyon, France; ⁴⁹Clinique Saint Pierre, Perpignan, France; ⁵⁰Hospital St. Joseph, Marseille, France; ⁵¹Bayonne Hospital, France; ⁵²Hospital Clairval, Marseille, France; ⁵³University Hospital Lille, France; ⁵⁴Clinique Ambroise Paré, Paris, France; ⁵⁵Clinique Pôles Santé République, Clermont Ferrand, France; ⁵⁶Centre Cardiologie du Nord, Saint Denis, France; ⁵⁷Barts Heart Centre, Barts Health NHS Trust, London, UK; ⁵⁸William Harvey Heart Centre, Queen Mary University of London, UK; ⁵⁹Royal Papworth Hospital, Cambridge, UK; ⁶⁰Department of Heart Disease, Haukeland University Hospital, University of Bergen, Bergen, Norway; ⁶¹Department of Cardiology, University Medical Center Ljubljana, Slovenia; ⁶²University of Patras, Greece; ⁶³Heart Rhythm Management Center, Dokuz Eylül University, Izmir, Turkey; ⁶⁴Department of Cardiology, Hacettepe University, Ankara, Turkey; ⁶⁵Department of Cardiology, Division of Arrhythmia and Electrophysiology, University of Health Sciences, Yuksek Ihtisas Cardiovascular Building, Ankara City Hospital, Ankara, Turkey; ⁶⁶Cerrahpasa Faculty of Medicine, Department of Cardiology, Istanbul University-Cerrahpasa, Istanbul, Turkey; ⁶⁷Department of critical care medicine, Faculty of medicine, Cairo University, Cairo, Egypt; ⁶⁸Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Centre for Heart Diseases, Zabrze, Poland; ⁶⁹Department of Cardiology, Japanese Red Cross Saitama Hospital, Japan; ⁷⁰Division of Cardiology, Saiseikai Kumamoto Hospital, Kumamoto, Japan; ⁷¹Department of Cardiology, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan; ⁷²UCLA Cardiac Arrhythmia Center, Los Angeles, USA; ⁷³University of Florida Health, Jacksonville, FL, USA; ⁷⁴Icahn School of Medicine at Mount Sinai, New York, NY, USA; ⁷⁵St. David's Medical Center, Texas Cardiac Arrhythmia Institute, Austin, TX, USA; ⁷⁶International Electrophysiology, Scripps Clinic, San Diego, CA, USA; ⁷⁷Metro Health Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA; ⁷⁸Department of Cardiology, Kepler University Hospital, Linz, Austria; ⁷⁹Department of Cardiology, Shanghai East Hospital, Tongji University, Shanghai, China; ⁸⁰Department for Electrophysiology, Heart Center University Cologne, Cologne, Germany; and ⁸¹La Paz University Hospital, Universidad Autónoma de Madrid, Idipaz, Madrid, Spain

Received 24 February 2023; revised 10 April 2023; accepted 14 April 2023; online publish-ahead-of-print 16 April 2023

See the editorial comment for this article 'Putting fear into perspective: estimating the true incidence of oesophageal fistula formation post-atrial fibrillation ablation', by M.W. Lim and J.M. Kalman, <https://doi.org/10.1093/eurheartj/ehad309>.

Abstract

Aims

Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. Data on its incidence, management, and outcome are sparse.

Methods and results

This international multicentre registry investigates the characteristics of oesophageal fistulae after treatment of atrial fibrillation by catheter ablation. A total of 553 729 catheter ablation procedures (radiofrequency: 62.9%, cryoballoon: 36.2%, other modalities: 0.9%) were performed, at 214 centres in 35 countries. In 78 centres 138 patients [0.025%, radiofrequency: 0.038%, cryoballoon: 0.0015% ($P < 0.0001$)] were diagnosed with an oesophageal fistula. Peri-procedural data were available for 118 patients (85.5%). Following catheter ablation, the median time to symptoms and the median time to diagnosis were 18 (7.75, 25; range: 0–60) days and 21 (15, 29.5; range: 2–63) days, respectively. The median time from symptom onset to oesophageal fistula diagnosis was 3 (1, 9; range: 0–42) days. The most common initial symptom was fever (59.3%). The diagnosis was established by chest computed tomography in 80.2% of patients. Oesophageal surgery was performed in 47.4% and direct endoscopic treatment in 19.8% and conservative treatment in 32.8% of patients. The overall mortality was 65.8%. Mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared to conservative management (89.5%) [odds ratio 7.463 (2.414, 23.072) $P < 0.001$].

Conclusion

Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.

Structured Graphical Abstract

Key Question


Oesophageal fistula represents a rare but dreadful complication of atrial fibrillation catheter ablation. The POTTER-AF study aimed to investigate the characteristics of oesophageal fistulae following catheter ablation in a large multinational registry.

Key Finding

Oesophageal fistula after catheter ablation of atrial fibrillation was rare (incidence: 0.025%) and occurred mostly with the use of radiofrequency energy (0.038%) rather than cryoenergy (0.0015%, $p < 0.0001$). The mortality without surgical or endoscopic intervention was exceedingly high (89.5%).

Take Home Message

Oesophageal fistula after catheter ablation of atrial fibrillation is rare and occurs mostly with the use of radiofrequency energy rather than cryoenergy. Mortality without surgical or endoscopic intervention is exceedingly high.



Summary of the POTTER-AF study results. CI, confidence interval; OR, odds ratio.

Keywords

Atrial fibrillation • Catheter ablation • Radiofrequency energy • Oesophageal fistula

Introduction

Invasive treatment of atrial fibrillation (AF) by catheter ablation based pulmonary vein isolation (PVI) is being increasingly performed worldwide. Catheter ablation has shown high procedural and long-term follow-up success rates for treatment of paroxysmal and persistent AF.¹ In general, the rate of severe peri- and post-procedural complications is low, and several technical improvements, novel technologies, and energy sources have increased the safety profile of this treatment strategy. However, oesophageal fistula (OF) is a devastating and potentially lethal complication of AF ablation procedures. Its incidence is known to be low and has been reported to range between 0.02% and 0.1% of cases, with a high mortality of

50% to 83%.²⁻⁵ Since OF is a rare complication, only limited information based on case reports, case series, and nationwide registries with a limited number of patients on its incidence, management, and outcome is available in the recent literature.^{2,3,6-12} The largest survey to date was conducted in 2015 and included 33 patients with OF after AF ablation.³ Meanwhile, the total number of AF ablation procedures has significantly increased. Additionally, AF ablation technologies have rapidly changed with increasing numbers of cryoballoon ablations, contact force guidance, and high-power short-duration based radiofrequency (RF) ablations.¹³⁻¹⁵ The aim of this worldwide study was to evaluate the incidence, management, and outcome of OF after catheter ablation procedures for AF or atrial tachycardia (AT) treatment.

Methods

Study design

The Prognosis following oesophageal fistula formation in patients undergoing catheter ablation for AF (POTTER-AF) study is designed as an international, multi-centre, anonymized registry study to evaluate the incidence, management and outcomes of post-procedural OF after catheter ablation of AF. The survey was conducted at the Department of Rhythmology at the Lübeck University Heart Center under the auspices of the Working Group of Cardiac Electrophysiology of the German Cardiac Society (AGEP, DGK). Experienced electrophysiological centres from all around the world were invited to participate. The registry was approved by the local ethical review board of the University of Lübeck, Germany (AZ 21–291). Each participating centre was responsible for its ethics approval by the local ethics committee. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All patient information was anonymized. The POTTER-AF study has been registered at clinicaltrials.gov (NCT05273645). Each participating centre provided data on the total number of patients treated with catheter ablation for AF or AT. Additionally, patients' baseline characteristics, peri-procedural characteristics, and follow-up data were assessed for patients with OF according to a standardized and uniform online questionnaire survey (SurveyMonkey). Data acquired via SurveyMonkey were assessed for an individual patient level and used for further analysis. The inclusion criteria were patients with an OF (which included atrio-OF, oesophago-pericardial fistula, or oesophageal perforation) after catheter ablation for AF treatment. There were no exclusion criteria for this study. The primary endpoint was the occurrence of OF following catheter ablation for AF or AT treatment. The secondary endpoints were the diagnosis and management of OF as well as outcome and mortality.

Data management

Data were retrospectively and electronically collected. The analysis was performed using anonymized data only. The described data were retrospective data derived from the clinical routine of the participating centres, including routine follow-up visits. All the members of the research team were obliged to secrecy. All data were protected from unauthorized external access, as only members of the research team were permitted and enabled access to these data.

Statistical analysis

All categorical variables were reported as absolute and relative frequencies and were compared using Fisher's exact test or the χ^2 test. Continuous variables were tested for normal distribution using the Shapiro–Wilk test. They were reported as mean \pm standard deviation (SD) in the case of normal distribution, otherwise as median and interquartile range (first quartile, third quartile). Continuous variables were compared using the non-paired Student's *t*-test when normally distributed and the corresponding non-parametric test (Mann–Whitney *U* test) otherwise.

The association between different parameters and death was assessed using binary logistic regression and is reported as odds ratio (OR) and 95% confidence intervals (CIs).

Variables with a *P*-value <0.1 in the univariable model and considered clinically important for the outcome were included in a multivariable binary logistic regression model.

All parameters with perfect collinearity were excluded from the logistic regression analysis and were reported descriptively. The variables eligible for multivariable logistic regression are as follows: age, structural heart disease, left ventricular ejection fraction, coronary artery disease, congestive heart failure, duration of hospitalization, use of conscious sedation, use of thermal probe, anatomical PVI, and diagnostic method [computed tomography (CT), septic shock, coma, cardiac arrest, oesophageal surgery, direct oesophageal surgery without endoscopic treatment, conservative treatment]. All *P*-values are two sided. A *P*-value of <0.05 was considered

statistically significant. All statistical analyses were performed using SPSS version 28.0 (IBM SPSS Statistics).

Results

Patients' population

A total of 609 experienced electrophysiological centres around the world were invited to participate in this study (Figure 1). Data on overall conducted AF or AT catheter ablation procedures were obtained from 214 (35%) centres in 35 countries across 5 continents. The full list of centres included in this study is available in the supplementary data (see [Supplementary data online, Table S1](#)). A total of 553 729 patients underwent catheter ablation procedures for AF or AT treatment between 1996 and 2022. The mean percentage of energy source was RF in $62.9\% \pm 29.8\%$, cryoballoon in $36.2\% \pm 30\%$, laserballoon in $0.6\% \pm 3\%$, and others in $0.3\% \pm 1.3\%$. A total of 138 patients (0.025%) from 78 centres (21 countries) experienced post-procedural OF (Figure 2). The incidence of RF was 0.038%, while for cryoballoon it was 0.0015% ($P < 0.0001$). For other modalities, the incidence was 0.02%.

Peri-procedural data, management, and outcomes were available for 118 patients (18 countries), while relevant data were not available for 20 patients (14.5%). The final diagnoses were atrio-OF in 113/118 (95.8%) patients, oesophago-pericardial fistula in 4/118 (3.4%) patients, and oesophageal perforation in 1 (0.8%) patient. The baseline characteristics are shown in Table 1. Forty-seven percent were female, with a mean age of 62.0 ± 11.4 years. A history of oesogastric pathology was reported in 8% of the patients, and 23% reported a pre-procedural proton pump inhibitor therapy.

The highest amount of OF per centre was five in one centre. The maximum incidence of OF at the specified time was 0.4%, whereas the minimum incidence per study centre was 0.0066% ($P < 0.01$).

Peri-procedural characteristics

Procedural data are presented in Table 2. In 114/118 patients (96.6%), the catheter ablation energy source was RF; contact force measuring catheters were used in 46% of them. The median RF power when ablating at the posterior wall was 30 (interquartile range: 25, 30) W. Besides PVI, additional left atrial (LA) lines were deployed in 45.5% of RF patients. Ablation of a roof line was performed in 30.9%, a posterior line was performed in 24.5%, and ablation of complex fractionated atrial electrograms at the posterior wall was performed in 15.2% of patients.

In 3/118 patients (2.5%), a cryoballoon ($n = 1$: first generation, Arctic Front cryoballoon, Medtronic Inc. and $n = 2$: second generation Arctic Front Advanced cryoballoon, Medtronic Inc.) was used for PVI. The minimal reported temperature was -69°C during cryoballoon application to the RIPV. No oesophageal temperature probe was utilized in any of the cryoballoon OF cases. In 1/118 patients (0.8%), the laserballoon ablation (HeartLight, Cardiofocus) was used. The maximal laser energy at the posterior wall was reported to be 10 W, and the maximal oesophageal temperature as measured via an oesophageal temperature probe was reported to be 37.1°C . An oesophageal temperature probe was utilized in 24.6% of the total OF population, and data concerning the oesophageal temperature were available for 15.3% of patients. The mean maximum measured temperature was $40.2^\circ \pm 2.2^\circ\text{C}$. A total of 74.6% reported post-procedural proton pump inhibitor therapy.

Patient presentation

The findings on patients' presentation, diagnostic modality, and complications are depicted in Figure 3. The median time between the procedure




Figure 1 Flowchart of the POTTER-AF study. AF, atrial fibrillation; OF, oesophageal fistula; CT, computed tomography.




Figure 2 (A) Endoscopic view of the oesophagus in a patient with an atrio-oesophageal fistula. (B) Intraoperative situ during oesophageal surgery in a patient with an atrio-oesophageal fistula.

and earliest onset of symptoms was 18 (7.75, 25) days (range: 0–60 days), and the median time between the procedure and OF diagnosis was 21 (15, 29.5) days (range: 2–63 days). The median time from first symptom onset to OF diagnosis was 3 (1, 9) days (range: 0–42 days). One OF occurred on Day 2 (RF, non-contact force catheter, maximum of 25 W at

posterior wall, PVI only). The first symptoms occurred already on Day 1 (fever, neurological symptoms, multi-organ dysfunction, septic shock, and death before interventional or surgical treatment). Two further OF were diagnosed on Day 4 and two OF on Day 5. All early diagnosed patients reported symptoms (fever and neurological symptoms).

Table 1 Baseline characteristics

Characteristics	All patients	Survivors	Non-survivors	P-value
Number of patients	118	40	77	
Age, years	62.0 ± 11.4	58.8 ± 12.4	64 ± 10.5	0.045
Female sex	55 (47)	20/40 (50)	35/76 (46.1)	0.700
Body mass index, kg/m ²	26.4 (23.6, 28.9)	26.6 (24.6, 29.1)	26.1 (23.1, 28.8)	0.772
Paroxysmal AF	49 (42)	19/40 (47.5)	30/77 (39)	0.432
Persistent AF	61 (52)	19/40 (47.5)	41/77 (53.2)	0.566
Long standing persistent AF	8 (7)	2/40 (5)	6/77 (7.8)	0.714
Structural heart disease	36 (31)	8/40 (20)	28/76 (36.8)	0.090
Coronary artery disease	20/112 (18)	2/38 (5.3)	18/73 (24.7)	0.017
Congestive heart failure	20/115 (17)	3/39 (7.7)	17/76 (22.4)	0.068
LA surface, cm ²	25.5 ± 15.4	25.32 ± 8.3	34.5 ± 20.2	0.0830
LA volume, ml	132.6 ± 57.9	199 ± 31.5	125.2 ± 29.6	0.0041
LVEF, %	60 (50, 65)	60 (55, 65)	60 (50, 60)	0.038
CHA ₂ DS ₂ -VASc score	2.1 ± 1.4	1.9 ± 1.3	2.3 ± 1.4	0.192
Arterial hypertension	70/117 (60)	23/40 (57.5)	47/76 (61.8)	0.692
Type II diabetes mellitus	17 (14)	5/40 (12.5)	12/76 (15.8)	0.785
Chronic kidney disease	10/91 (11)	1/29 (3.4)	9/61 (14.8)	0.158
History of oesogastric pathology	9/109 (8)	1/38 (2.6)	8/70 (11.4)	0.156
Pre-procedural PPI therapy	25/110 (23)	6/38 (15.8)	19/71 (26.8)	0.237
OF after 1st ablation procedure	105 (89)	37/40 (92.5)	67/77 (87)	0.538
OF after >1st ablation procedure	13 (11)	3/40 (7.5)	10/77 (13)	0.538

Values are counts, *n* (%), mean ± SD, or median (first quartile, third quartile).

AF, atrial fibrillation; LA, left atrium; LVEF, left ventricular ejection fraction; TIA, transitory ischaemic attack; PPI, proton pump inhibitors; OF, oesophageal fistula.

In patients treated with endoscopy alone, oesophageal surgery, or conservative treatment, the median time between the procedure and the earliest onset of symptoms was 10 (6, 15), 18 (11, 22.5) and 20.5 (10, 29) days, respectively ($P = 0.03$). The median times between the procedure and OF diagnosis were 18 (10, 25), 21 (15, 29) and 26.5 (19, 32) days, respectively ($P = 0.03$).

The primary initial symptoms were fever ($n = 70$, 59.3%), chest pain or odynophagia ($n = 64$, 54.2%), and neurological symptoms (stroke or seizures) ($n = 52$, 44.1%). Other symptoms were reported in 74 patients (62.3%: dyspnoea, nausea, syncope, cough, AF, haematemesis, confusion, vomiting, ST-elevation myocardial infarction, and aphasia). The symptoms occurred either in isolation or in association with one another. In one patient (0.8%), no symptoms were reported. Diagnosis was made by routine endoscopy on Day 10. In this case, a RF contact force measuring catheter with a maximum of 48 W at the posterior wall during deployment of a posterior line was utilized. After endoscopic treatment via clipping, no sequelae was reported.

The diagnosis was established by chest CT in 93 (80.2%) patients, with cerebral CT or cerebral magnetic resonance imaging in 40 (34.5%), with echocardiography in 29 (25%), with endoscopy in 24 (20.7%) patients, and other, in 20 (17.2%, autopsy, peri-cardiocentesis, lumbar puncture, cardiac surgery) of patients. Diagnosis was

established using either an isolated modality or a combination of several modalities.

Clinical course, management, and outcome

During the clinical course, delayed complications were stroke or cerebral haemorrhages (25/107, 23.4%), severe sepsis or septic shock (62/107, 57.9%), coma (50/107, 46.7%), cardiac arrest (20/107, 18.7%), gastrointestinal bleeding (18/107, 16.8%), cardiac tamponade (12/107, 11.2%), or others in 31/107 (29%). A total of 5/107 (4.7%) patients reported no complications. In two of those patients, the OF was detected during routine endoscopic ultrasound assessment and was treated by endoscopic clipping and endoscopic stenting with no and minor sequelae, respectively. In one patient, a CT scan was performed due to confusion. After detection of an OF, the patient was treated with endoscopic stenting followed by oesophageal surgery with minor long-term sequelae. Gastric liquid pericardial effusion was detected in two patients; both treated with oesophageal surgery and did not report any sequelae.

All patients were treated with intravenous antibiotic therapy. Among 116 patients diagnosed with OF, and treatment data available, $n = 38$ (32.8%) were treated conservatively, without endoscopic or surgical

Table 2 Procedural data

Characteristics	All patients	Survivors	Non-survivors	P-value
Usage of general anaesthesia	56 (47.5)	18/40 (45)	38/77 (49.4)	0.700
Usage of deep analgesedation	35 (29.7)	12/40 (30)	23/77 (29.9)	1.000
Procedure time, min	147 (108, 180)	135.5 (108.5, 177.5)	150 (110.3, 191.3)	0.124
RF energy	114 (96.6)	39/40 (97.5)	74/77 (96.1)	1.000
RF duration, min	38.5 (23.8, 52.6)	31 (22.5, 51)	43.5 (27, 53.9)	0.217
RF contact force catheter	52/113 (46.0)	17/39 (43.6)	35/73 (47.9)	0.695
RF power on LA posterior wall, Watts	30 (25, 30)	30 (25, 35)	30 (25, 30)	0.404
Circumferential PVI	102/109 (93.6)	33/36 (91.7)	68/72 (94.4)	0.684
Segmental ostial	2/109 (1.8)	0/36 (0)	2/72 (2.8)	0.551
Anatomical ostial	6/109 (5.5)	4/36 (11.1)	2/72 (2.8)	0.094
Additional LA line ablation	50/110 (45.5%)	20/37 (54.1)	30/72 (41.6)	0.231
Roof line	34/110 (30.9)	10/37 (27)	24/72 (33.3)	0.663
Posterior line	27/110 (24.5)	10/37 (27)	17/72 (23.6)	0.815
Anterior lines	8/110 (7.3)	0/37 (0)	8/72 (11.1)	0.049
Inferior lines	2/110 (1.8)	1/37 (2.7)	1/72 (1.4)	1.000
Mitral isthmus line	4/110 (3.6)	1/37 (2.7)	3/72 (4.2)	1.000
CFAE ablation at the LA posterior wall	12/79 (15.2)	2/25 (8)	10/53 (18.9)	0.319
Cryoballoon	3 (2.5)	0/40 (0)	3/77 (3.9)	0.550
1st generation cryoballoon	1/3 (33.3)	0	1/3 (33.3)	
2nd generation cryoballoon	2/3 (66.6)	0	2/3 (66.6)	
Range minimal temperature, C°	-69--47		-69--47	
Laserballoon	1 (0.8)	1/40 (2.5)	0/77 (0)	0.342
Maximal laser energy, Watts	10	10		
Usage of oesophageal temperature probe	29 (24.6)	14/40 (35)	15/77 (19.5)	0.075
Maximal temperature, C°	40.2 ± 2.2	39.9 ± 2.6	40.7 ± 1.6	0.481
Post-procedure prescription of PPI	85/114 (74.6)	29/39 (74.4)	56/75 (74.7)	1.000

Values are counts, *n* (%), mean ± SD, or median (first quartile, third quartile).

CFAE, complex fractionated atrial electrograms; LA, left atrium; PVI, pulmonary vein isolation; PPI, proton pump inhibitors; RF, radiofrequency.

treatment attempts, and *n* = 34 (89.5%) of them died during follow-up. One patient (2.6%) had severe sequelae, and three (7.9%) reported no long-term sequelae.

A total of 31 (26.7%) patients were initially treated with endoscopic therapy [oesophageal stenting (*n* = 28), clipping (*n* = 2), or vacuum-assisted-closure therapy (*n* = 1)]. Due to their critical condition, 17/31 (54.8%) died or had severe sequelae (3/31, 9.7%). Minor sequelae were reported in 4/31 (12.9%) patients, while 7/31 (22.6%) had no sequelae. The oesophageal stent was removed in 4/31 (12.9%) patients after 30–75 days.

Isolated endoscopic therapy was performed in 23 (19.8%) patients (mortality: 13/23, 56.5%), whereas in eight patients the initial endoscopic therapy was switched to a surgical approach due to limited benefit (mortality: 4/8, 50%).

A total of 55/116 (47.4%) patients were treated using an oesophageal surgical approach. In one patient treated with oesophageal

surgery, the data concerning mortality were not available. A total of 28/54 (51.9%) patients treated surgically died. A direct surgical approach without a previous endoscopic treatment attempt was conducted in 47/116 (40.5%) patients. In this group, 24/46 (52.2%) died. In terms of mortality, there were no significant differences between patients who underwent a direct surgical approach and those who underwent a direct endoscopic approach (*P* = 0.801). The overall mortality was 77/117 (65.8%), 11/117 (9.4%), and 11/117 (9.4%) experienced long-term major and minor sequelae, respectively. Only 18/117 (15.4%) reported no long-term sequelae. The mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower than that following conservative management (89.5%) [OR 7.463 (2.414, 23.072) *P* < 0.001] (Figure 4). The median time to death was 28.5 days (19.3, 42).

In order to better understand the differences between patients receiving conservative treatment and those receiving surgical/endoscopic




Figure 3 (A) Time to first symptoms and time to diagnosis. Overview of the clinical presentation (B), utilized diagnostic modalities (C), and complications (D) of all patients with oesophageal fistula ($n = 118$). Multiple symptoms were possible.




Figure 4 (A) Overview of the different treatment strategies and outcome of patients. (B) Outcome of all patients with oesophageal fistula.

treatment, the comparison between the two populations in terms of baseline characteristics, procedural data, complications, and survival was performed (see [Supplementary data online, Table S4](#)). It is important to note that the patients receiving conservative treatment had a longer time to initial symptoms [20.5 (10, 29.8) vs. 15 (6, 21.8) days; $P = 0.037$] and a longer time until OF diagnosis [26 (18, 33.5) vs. 19 (13, 28.5) days; $P = 0.019$], as compared to those receiving surgical/

endoscopic treatment. Moreover, the patients receiving invasive treatment were more likely to be diagnosed by means of chest CT (86.8% vs. 65.8%; $P = 0.013$) and less likely to be diagnosed by other methods. In terms of complications, the patients receiving surgical/endoscopic treatment were less likely to have a diagnosis of stroke during the clinical course as compared to those treated conservatively (14.7% vs. 39.5%; $P = 0.008$).

Subgroup analysis of survivors vs. non-survivors

A detailed comparison of survivors and non-survivors is shown in [Supplementary data online, Table S2](#). Concerning baseline characteristics, atrio-OF, older age, reduced left ventricular ejection fraction, and coronary artery disease showed significantly higher values in terms of mortality, while an oesophageal-pericardial fistula ($n = 4$ patients, 100% survival) showed a significantly lower mortality. An anterior line showed significantly higher mortality. The occurrence of septic shock, coma, cardiac arrest, and gastrointestinal bleeding was significantly higher in the non-survivors, while the rate of patients with no complications was significantly higher in the survivors. Patients with any interventional or surgical treatment, patients with oesophageal surgery as well as patients with direct oesophageal surgery without previous stenting or clipping showed a significantly lower mortality.

To identify mortality associated factors, a simple (univariable) binary logistics regression was performed (see [Supplementary data online, Table S3](#)). For identified factors with a P -value of <0.1 and considered of clinical importance for the prognosis, a multivariable binary logistic regression was conducted.

Although not significant, yet a trend towards a lower mortality was observed for the use of an oesophageal probe (OR: 0.449, $P = 0.068$) in the univariable logistic regression. After including this variable in the multivariable model, it was significantly associated with lower mortality (OR: 0.231, $P = 0.012$). Moreover, the use of conscious sedation and the treatment via oesophageal surgery were associated with better survival ([Table 3](#)).

Discussion

OF represents a rare but dreadful complication of AF catheter ablation. The incidence varies between different studies; however, it may be underreported and the true incidence is unknown. This fearful complication is associated with a very high mortality rate.²⁻⁵ Due to the limited number of cases, data concerning the incidence, management, and outcome of OF are sparse. Therefore, this complication requires an international worldwide effort to allow for a better understanding of the factors contributing to its occurrence and the optimal management

strategies. To address these issues, the POTTER-AF study was conducted.

The major findings were: (i) the incidence of OF after catheter ablation for AF/AT treatment was 0.025% with an incidence of 0.038% for RF and 0.0015% for Cryoballoon ($P < 0.0001$); (ii) the median time to symptoms [18 (7.75, 25) days], and the median time to diagnosis [21 (15, 29.5) days] occurred relatively late after the procedure, while the median time from first symptom onset to OF diagnosis was 3 (1, 9) days (range: 0–42 days); (iii) the most common initial symptom was fever (59.3%); (iv) the diagnosis was established using chest CT in 80.2%; (v) oesophageal surgery was performed in 47.4% and a direct endoscopic treatment was conducted in 19.8%, and conservative treatment was conducted in 32.8% of cases; (vi) the overall mortality was 65.8%, 18.8% experienced long term sequelae; (vii) mortality following surgical (51.9%) or endoscopic treatment (56.5%) was significantly lower as compared with conservative management (89.5%) ($P < 0.001$); and (viii) the multivariable binary logistic regression found the conscious sedation and the use of thermal probe, as well as the treatment by means of oesophageal surgery as significantly associated with a better prognosis in terms of survival ([Structured Graphical Abstract](#)).

This worldwide survey provides the largest dataset on OF today. It reports important data to allow a better understanding of the incidence, management, and outcomes of OF occurring after AF/AT ablation. With 0.025%, the incidence of OF is in line with recent literature of a nationwide survey from France (incidence of 0.026%), which was calculated from 33 OF in 129 286 AF/AT ablations procedures.³ Other surveys with limited patients number reported on incidences of between 0.016% and 0.15%.^{2,7,16}

Impact of the energy source in oesophageal fistula formation

Although OF has been mainly reported for RF based catheter ablation procedures, the latest findings suggest that OF also may occur in cryoballoon and other balloon-based ablation procedures.^{10,17} The incidence of OF following cryoballoon based ablation was reported as $<0.0001\%$, which maybe reflects the frequent use of oesophageal temperature probes during cryoballoon based procedures.¹⁰ The POTTER-AF study evaluated an OF in a total of 3 patients after cryoballoon based PVI which only reflects 2.5% of the analysed population. The incidence of RF (0.038%) was significantly higher than that of cryoballoon (0.0015%, $P < 0.0001$). This difference might partially be explained by additional ablation of LA lines in RF patients, yet most likely not completely. With a reported cryoballoon temperature of a minimum of -69°C , which is far below the suggested minimum temperature of -60°C for the Arctic Front Advanced cryoballoon, the combination of a temperature cut-off and the utilization of an oesophageal temperature probe might prevent OF in cryoballoon procedures. In 1/118 patients (0.8%), the laserballoon ablation was used. The maximal laser energy at the posterior wall was reported to be 10 W, which is in line with the recommendations.¹⁸

Since RF is still the most common energy source for cardiac ablation procedures, and the main proportion of patients included in the POTTER-AF study suffered OF after RF-based catheter ablation. The latest observations on pulsed field ablation based catheter ablation suggested that this novel non-thermal energy source might reduce oesophageal injuries and potentially OF due to its selectivity to cardiomyocytes.¹⁹

Table 3 Multivariable binary logistic regression

Characteristics	OR	95% CI	P-value
Age (years)	1.039	0.995–1.084	0.081
LVEF (%)	0.992	0.942–1.044	0.748
Coronary artery disease	3.096	0.555–17.259	0.197
Congestive heart failure	2.625	0.555–12.411	0.223
Conscious sedation	0.229	0.060–0.865	0.030
Use of thermal probe	0.231	0.074–0.724	0.012
Diagnostic: CT	0.371	0.093–1.481	0.160
Oesophageal surgery	0.329	0.123–0.881	0.027

The continuous variables have the unit of measurement in brackets. All other variables are categorical variables.

CI, confidence interval; CT, computed tomography; OR, odds ratio; LVEF, left ventricular ejection fraction.

Prevention of oesophageal fistula

Utilization of oesophageal temperature probes is a common strategy to monitor the oesophageal temperature and potentially prevent oesophageal injuries. While for cryoballoon and laserballoon-based ablation, the use of an oesophageal temperature probe is a commonly accepted strategy. However, its usage during RF based ablation is less common, and one study showed that it could be a risk factor for the development of endoscopically detected esophageal lesions.²⁰ However, in general, the use of a temperature probe seems to be a potential way to reduce the risk of oesophageal overheating and cooling and therefore a potential strategy to prevent oesophageal injuries. In the POTTER-AF study, an oesophageal temperature probe was utilized in 24.6% of POTTER-AF patients, and the mean maximal measured temperature was $40.2 \pm 2.2^\circ\text{C}$.

Clinical presentation and diagnostics

Although the pathophysiology of OF development is not completely understood, there is agreement that ablation energy from any source delivered to the posterior LA wall leads to thermal damage to the oesophagus. Since lesion formation requires time to progress, the first symptoms typically occur within 60 days after the procedure.²¹ The symptoms are diverse and not specific, consisting primarily of fever and neurological abnormalities, sometimes mimicking a cerebral vascular accident.²² The findings of POTTER-AF are in line with these observations since most patients reported fever (59.3%), chest pain/odynophagia (54.2%), and neurological signs (44.1%). With a median of 18 (7.75, 25) days (range 0–60), the observed time to symptoms was shorter than previously reported. Additionally, the time to diagnosis [median 21 (15, 29.5) days, range: 2–63 days] and time from first symptom onset to OF diagnosis [3 (1, 9) days (range: 0–42 days)] were relatively short but showed a relatively wide range. This observation might reflect the possibility that some patients presented at hospitals where they had not received the catheter ablation procedure which might lead to a longer time to diagnosis compared to the patients who presented at experienced electrophysiological centres who are potentially more aware of OF. In order to plan rapid treatment of OF, it is essential to detect this complication early. In more than 80% of patients, a chest CT was the most common diagnostic method, which has been previously recommended by other authors. In the CT scan, signs such as oesophageal opacification and air detected inside the left atrium are highly suggested to be associated with OF. It is important to state that endoscopy is discouraged that air should not be injected into the oesophagus due to the potential development of air embolism.

Treatment strategies and outcome

Since most patients reported fever and developed sepsis and/or septic shock, all patients were treated with antibiotics. The overall mortality was 65.8%, with significantly reduced mortality in patients undergoing surgical repair (51.9%) compared with endoscopic treatment only (56.5%) and conservative management (89.5%) [OR 7.463 (2.414, 23.072) $P < 0.001$], compared with conservative treatment).

Although these observed improvements in mortality are highly significant, the reason for the different treatment strategies shows a selection bias, since patients who were not able to undergo any oesophageal surgery or endoscopic treatment and received conservative treatment due to critical illness had the worst outcome. In fact, the time to the earliest onset of symptoms and the time to OF diagnosis were the shortest in patients who received endoscopic treatment only followed

by oesophageal surgery and conservative treatment. Patients with an early OF detection received an early treatment via endoscopy or oesophageal surgery with a lower mortality while patients with late detection more often received a conservative treatment with a higher mortality. This observation again underlines the importance of early diagnosis, detection, and treatment of OF. The findings of the multivariable binary logistic regression analysis detected an intervention of OF patients via an oesophageal surgery as a factor that was associated with a lower mortality. Coronary artery disease, coma, and cardiac arrest were identified as the factors associated with a higher mortality. The use of an oesophageal thermal probe and the use of conscious sedation were also associated with better survival.

These observations are in line with a large meta-analysis conducted in 2017 with 120 reported OF cases from a total of 85 studies. The overall mortality was reported to be 55%, with significantly reduced mortality in patients undergoing surgical repair (33%) compared to endoscopic treatment (65%) and conservative management (97%).²¹

Limitations

The POTTER-AF study has several limitations. First, the findings were based on a retrospective analysis. Nevertheless, the data were obtained from a large number of centres across the globe represent the largest database on OF up to date. Second, since only data from patients with peri-procedural OF were collected, we were unable to assess predictors of its occurrence. Third, not all data were available and some patients were lost to follow-up. Fourth, because OF typically occurs relatively late after the procedure, the incidence may be underreported, and the true incidence remains unknown. Fifth, there were no data on how the temperature measured by the oesophageal temperature probe was utilized in these patients, and no cut-off values were available. Sixth, no accurate data were available reporting on the specific ablation design for the participating centres. Seventh, no subgroup analysis on the incidence of the use of contact force catheters, ablation index, and lesion size index was available. Eighth, the absence of data from a significant proportion of invited centres strongly limits the applicability of the present results to a general population and may result in underestimation of the true incidence of OF. Finally, our findings concerning different treatment strategies and outcomes show the above-mentioned selection bias concerning critical illness and operability of the patients.

Conclusions

In this large worldwide registry, the incidence of OF was very low; in general, the incidence was lower for cryoballoon- compared to RF-based procedures. The observed time to symptoms was shorter than previously reported. Additionally, the time to diagnosis and the time from first symptom onset to OF diagnosis were relatively short but showed a relatively wide range. The overall prognosis was poor. Surgical or endoscopic intervention is mandatory for improving patient survival.

Acknowledgements

We thank all the local investigators and assistant personnel for their great effort. Furthermore, we thank all the POTTER-AF collaborators listed in the [Supplementary data online, Table S2](#).

Supplementary data

[Supplementary data](#) is available at *European Heart Journal* online.

Pre-registered clinical trial number

The pre-registered clinical trial number is ClinicalTrials.gov Identifier: NCT05273645.

Ethical approval

The registry was approved by the local ethical review board of the University of Lübeck, Germany (AZ 21–291). Each participating centre was responsible for its ethics approval by the local ethics committee. The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. All patient information was anonymized.

Data availability

Non-digital data supporting this study are curated at the Study Center of the Department of Rhythmology, University Hospital Schleswig-Holstein, German.

Conflict of interest

R.R.T. is a consultant for Boston Scientific, Biotronik, and Biosense Webster and received speaker honoraria from Biosense Webster, Medtronic, Boston Scientific, and Abbot Medical. K.-H.K. reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster, outside the submitted work. C.H.H. received travel grants and research grants from Boston Scientific, Lifetech, Biosense Webster, and Cardiofocus and speaker honoraria from Medtronic, Boston Scientific, Biosense Webster, Cardiofocus and C.T.I. GmbH and Doctrina Med. He is a consultant of Boston Scientific, Lifetech, Biosense Webster, and Cardiofocus. H.P.—receipt of honoraria or consultation fees: Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, Pfizer, Abbott, Biosense-Webster, Boston Scientific, and Medtronic; participation in a company sponsored speaker's bureau: Biosense Webster, Abbott, Medtronic, Boston. M.M.—consultant and speaker: Abbott Medical, Biosense Webster, Medtronic, and Boston Scientific. P.S.—advisory Board für Biosense Webster, Boston Scientific, Abbott, und Medtronic. C.S. received research support and lecture fees from Medtronic, Abbott, Boston Scientific, and Biosense Webster. In addition, C.S. is a consultant for Medtronic, Boston Scientific, and Biosense Webster. C.V.—honoraria for training and consulting: Biotronik, Medtronic EG Unrelated to the topic: consulting fees from Medtronic, Boston, Microport, Abbott MG Speaker's honoraria/travel grants: Abbott, Biosense Webster, Boston Scientific, Medtronic, and Farapulse Inc. S.W.—consulting fees, Abbott, Biosense Webster, Boston Scientific, Bristol Myers Squibb, Boehringer Ingelheim, Medtronic, and Daiichi. Grants: Abbott, Boston Scientific. M.B. has received consultant honoraria and/or lecture honoraria and/or and travel grants from: Bayer, Novartis, Biosense Webster, Biotronik, and Boston Scientific. The following applies to both authors: there are no conflicts of interest with regard to this publication. L.I. has received consultant honoraria and/or lecture honoraria and/or and travel grants from: Abbott Medical, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Bristol-Myers-Squibb, Daiichi-Sankyo, Medtronic, and Novartis. A.F.—educational grant from Boston Scientific. S.R.—consultant for Medtronic, Abbott, and Biotronik, Member of the Medtronic European Conduction System Pacing Advisory Board. M.K.—honoraria for teaching, proctoring and lectures, honoraria for advisory board activities, participation in clinical trials, travel grants. A.F.—lecture fees and Consultant für Biosense Webster. C.W.—lecture fees from Biosense Webster. U.W.—lecture fees from Abbott Medical und Medtronic Inc. A.M.—consultant fees: Medtronic, CardioFocus, Biosense-Webster, and Boston Scientific. Travel grants and lecture honoraria: Medtronic, Cardiofocus, Biosense-Webster, Boston Scientific,

Lifetech, AstraZeneca, Boehringer Ingelheim, Bayer, and Philips-EPD. L.E.—discloses consultant fees, speaking honoraria, and travel expenses from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boehringer, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi Aventis. Research has been supported by German Research Foundation (DFG) and German Heart Foundation outside the submitted work. C.S. reports grants and lecture fees from Biosense Webster and Medtronic and served as a proctor for Biosense Webster and Medtronic. He also reports grants from the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel, and the University of Basel. M.K. reports grants from the Swiss National Science Foundation (Grant numbers 33CS30_148474, 33CS30_177520, 32473B_176178, 32003B_197524), the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel and the University of Basel, grants from Bayer, grants from Pfizer, grants from Boston Scientific, grants from BMS, grants from Biotronik, grants and personal fees from Daiichi Sankyo. L.R. has received speaker/consulting honoraria from Abbott/SJM and from Medtronic and has received a research grant for an investigator-initiated study to the institution from Medtronic. A.M.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board/consulting fees from Bayer Healthcare, Biotronik, Daiichi-Sankyo, Medtronic, Novartis, Pfizer and Stride Bio Inc. C.G.—research grants: MicroPort CRM. Consultant: MicroPort CRM, Boston Scientific, Abbott, Medtronic. Honoraria: Biotronik, Medtronic, Astra-Zeneca, BMS-Pfizer, Biosense-Webster. L.F. reports consulting fees for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novo Nordisk, and Novartis and lecture fees for AstraZeneca, Bayer, BMS/Pfizer, Boehringer Ingelheim and Zoll. S.B.—consultant for Medtronic, Boston Scientific, Microport, and Zoll. N.L.—consulting fees for Abbott Medtronic and Boston Scientific PJ Grant from Biosense Webster, Metronic, ABBOTT, Boston. N.D. consultant for Biosense Webster. C.M. BSCI, Medtronic, Biosense Webster, Adagio—speaker honoraria and consultancy fees. P.H. BSCI and Medtronic—speaker honoraria. J.C. serves as a consultant for Biosense Webster, Johnson & Johnson. G.L.—In general, I have received funding from Biosense Webster, Medtronic, and Abbott (speaker honoraria). E.E.Ö.—payment from healthcare industry to my institution for my personal services: honoraria, consultancy, advisory board: Biosense Webster, Medtronic. H.Y.—proctor for Abbott, Medtronic, and Biosense Webster. S.C.—travel grants and speaker's honoraria from Medtronic, Biosense Webster, and Abbott and is a proctor of Medtronic and Biotronik. E.J.—consultant fees from Biotronik, Medtronic, Abbott, Boston Scientific. K.O. received remuneration from Nippon Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Medtronic. J.N.C. Circa Scientific: research support. V.Y.R. does not report any disclosures directly related to this manuscript; but unrelated to this manuscript, he has served as a consultant for and has equity in Ablacon, Acutus Medical, Affera-Medtronic, Anumana, Apama Medical-Boston Scientific, APN Health, Aquaheart, Atacor, Autonomix, Axon Therapies, Backbeat, BioSig, CardiaCare, CardioNXT/AFTx, Circa Scientific, CoRISMA, Corvia Medical, Dinova-Hangzhou DiNovA EP Technology, East End Medical, EPD-Philips, EP Frontiers, Epix Therapeutics-Medtronic, EpiEP, Eximo, Farapulse-Boston Scientific, Field Medical, Focused Therapeutics, HRT, Intershunt, Javelin, Kardium, Keystone Heart, LuxMed, Medlumics, Middlepeak, Neutrace, Nuvera-Biosense Webster, Oracle Health, Restore Medical, Sirona Medical, SoundCath, Valcare; unrelated to this work, has served as a consultant for Abbott, AtriAN, Biosense-Webster, BioTel Heart, Biotronik, Boston Scientific, Cairdac, Cardiofocus, Cardionomic, CoreMap, Fire1, Gore & Associates, Impulse Dynamics, Medtronic, Novartis, Philips, Pulse Biosciences; and has equity in Manual Surgical Sciences, Newpace, Nyra Medical, Surecor, and Vizarmed'. A.N. consultant for Abbott, Baylis, biosense webster, biotronik, boston scientific and Medtronic DS research grant: Abbott, Medtronic, Johnson&Johnson; advisory board: Pfizer, Abbott; speaker fee: Abbott, Medtronic, Johnson&Johnson. J.L.M. received speaker fees and/or honoraria

for lectures and scientific advice from Biotronik, Medtronic, Microport, Milestone Pharmaceutical, Sanofi, and Zoll. K.H.K. reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster outside submitted work. All other authors have no relevant disclosures.

Funding

All authors declare no funding for this contribution.

References

- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;**42**: 373–498. <https://doi.org/10.1093/eurheartj/ehaa612>
- Ghia KK, Chugh A, Good E, Pelosi F, Jongnarangsin K, Bogun F, et al. A nationwide survey on the prevalence of atrioesophageal fistula after left atrial radiofrequency catheter ablation. *J Interv Card Electrophysiol* 2008;**24**:33–36. <https://doi.org/10.1007/s10840-008-9307-1>
- Gandjbakhch E, Mandel F, Dagher Y, Hidden-Lucet F, Rollin A, Maury P. Incidence, epidemiology, diagnosis and prognosis of atrio-oesophageal fistula following percutaneous catheter ablation: a French nationwide survey. *Europace* 2021;**23**:557–564. <https://doi.org/10.1093/europace/euab278>
- Cappato R, Calkins H, Chen S-A, Davies W, Ilesca Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol* 2009;**3**:32–38. <https://doi.org/10.1161/CIRCEP.109.859116>
- Chavez P, Messerli FH, Dominguez AC, Aziz EF, Sichrovsky T, Garcia D, et al. Atrioesophageal fistula following ablation procedures for atrial fibrillation: systematic review of case reports. *Open Heart* 2015;**2**:e000257. <https://doi.org/10.1136/openhrt-2015-000257>
- Nair KKM, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C, et al. The prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter ablation for atrial fibrillation: the Canadian experience. *J Interv Card Electrophysiol* 2013;**39**: 139–144. <https://doi.org/10.1007/s10840-013-9853-z>
- Barbhaiya CR, Kumar S, Guo Y, Zhong J, John RM, Tedrow UB, et al. Global survey of esophageal injury in atrial fibrillation ablation: characteristics and outcomes of esophageal perforation and fistula. *JACC Clin Electrophysiol* 2016;**2**:143–150. <https://doi.org/10.1016/j.jacep.2015.10.013>
- Kapur S, Barbhaiya C, Deneke T, Michaud GF. Esophageal injury and atrioesophageal fistula caused by ablation for atrial fibrillation. *Circulation* 2017;**136**:1247–1255. <https://doi.org/10.1161/CIRCULATIONAHA.117.025827>
- Mohanty S. Outcomes of atrio-esophageal fistula following catheter ablation of atrial fibrillation treated with surgical repair versus esophageal stenting. *J Cardiovasc Electrophysiol* 2014;**25**:E6. <https://doi.org/10.1111/jce.12494>
- John RM, Kapur S, Ellenbogen KA, Koneru JN. Atrioesophageal fistula formation with cryoballoon ablation is most commonly related to the left inferior pulmonary vein. *Heart Rhythm* 2017;**14**:184–189. <https://doi.org/10.1016/j.hrthm.2016.10.018>
- Tilz RR, Chun KRJ, Metzner A, Buchard A, Wissner E, Koektuerc B, et al. Unexpected high incidence of esophageal injury following pulmonary vein isolation using robotic navigation. *J Cardiovasc Electrophysiol* 2010;**21**:853–858. <https://doi.org/10.1111/j.1540-8167.2010.01742.x>
- Steinbeck G, Sinner MF, Lutz M, Müller-Nurasyid M, Käab S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. *Eur Heart J* 2018;**39**:4020–4029. <https://doi.org/10.1093/eurheartj/ehy452>
- Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *N Engl J Med* 2016;**374**: 2235–2245. <https://doi.org/10.1056/NEJMoa1602014>
- Kautzner J, Neuzil P, Lambert H, Peichl P, Petru J, Cihak R, et al. EFFICAS II: optimization of catheter contact force improves outcome of pulmonary vein isolation for paroxysmal atrial fibrillation. *Europace* 2015;**17**:1229–1235. <https://doi.org/10.1093/europace/euv057>
- Heeger CH, Sano M, Popescu SŞ, Subin B, Feher M, Phan HL, et al. Very high-power short-duration ablation for pulmonary vein isolation utilizing a very-close protocol—the FAST AND FURIOUS PVI study. *Europace* 2023;**25**:880–888. <https://doi.org/10.1093/europace/euac243>
- Kim YG, Shim J, Kim D, Choi J, Park S, Pak H, et al. Characteristics of atrial fibrillation patients suffering atrioesophageal fistula after radiofrequency catheter ablation. *J Cardiovasc Electrophysiol* 2018;**29**:1343–1351. <https://doi.org/10.1111/jce.13671>
- Sarairah SY, Woodbury B, Methachittiphan N, Tregoning DM, Sridhar AR, Akoum N. Esophageal thermal injury following cryoballoon ablation for atrial fibrillation. *JACC Clin Electrophysiol* 2020;**6**:262–268. <https://doi.org/10.1016/j.jacep.2019.10.014>
- Schmidt B, Metzner A, Chun KR, Leftheriotis D, Yoshiga Y, Fuernkranz A, et al. Feasibility of circumferential pulmonary vein isolation using a novel endoscopic ablation system. *Circ Arrhythm Electrophysiol* 2010;**3**:481–488. <https://doi.org/10.1161/CIRCEP.110.954149>
- Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). *Europace* 2022;**24**:1256–1266. <https://doi.org/10.1093/europace/euac050>
- Müller P, Dietrich J-W, Halbfass P, Abouarab A, Fochler F, Szöllösi A, et al. Higher incidence of esophageal lesions after ablation of atrial fibrillation related to the use of esophageal temperature probes. *Heart Rhythm* 2015;**12**:1464–1469. <https://doi.org/10.1016/j.hrthm.2015.04.005>
- Han HC, Ha FJ, Sanders P, Spencer R, Teh AW, O'Donnell D, et al. Atrioesophageal fistula: clinical presentation, procedural characteristics, diagnostic investigations, and treatment outcomes. *Circ Arrhythm Electrophysiol* 2017;**10**:e005579. <https://doi.org/10.1161/CIRCEP.117.005579>
- Pappone C, Vicedomini G, Santinelli V. Atrio-esophageal fistula after AF ablation: pathophysiology, prevention & treatment. *J Atr Fibrillation* 2013;**6**:860. <https://doi.org/10.4022/jafib.860>